Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A multiyear deal for mAbs
March 2017
SHARING OPTIONS:

VANCOUVER, British Columbia—AbCellera Biologics Inc. and Pfizer Inc. recently inked a therapeutic antibody discovery collaboration under which AbCellera will leverage its proprietary monoclonal antibody screening platform to discovery function-modulating antibodies against undisclosed membrane protein targets. Per the agreement, Pfizer will pay AbCellera an upfront payment and research support, with the potential for up to approximately $90 million in contingent milestone payments. AbCellera is also eligible to receive tiered mid-to-low single-digit royalty payments should Pfizer develop and commercialize antibodies generated under this deal.
 
“We are pleased to work with the team at AbCellera using their innovative antibody discovery platform,” said Will Somers, vice president of Biomedicines Design at Pfizer. “We hope this platform can aid in our research as we look to bring novel medicines to patients, seeking to discover modulators of a transmembrane protein in a therapeutically important target class.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.